News

News

Viglya wishes to establish transparent and open communication with its stakeholders. This section offers new and updated information regarding the company and the life science sector.

10.03.2014

AEMPS: Solicitudes de autorización de comercialización de medicamentos de uso humano. Monográfico de bases legales

Sorry, this entry is only available in Español.

LinkedIn1Twitter1Facebook0Google+0tumblr

Comments are closed.

AEMPS: Información a los Laboratorios Titulares de Medicamentos de Uso Humano que contienen “ibuprofeno” y “dexibuprofeno”. Acuerdo del CMDh de fecha 20.05.2015. (Nº EMA: EMEA/H/A-31/1401)
ANSM: Xgeva® 120 mg, solution injectable (denosumab) – Ajout d’une nouvelle contre-indication et remise d’une carte d’information patient
ANSM: Olmésartan: l’ANSM rappelle le risque de survenue d’entéropathie grave chez les patients traités par ces médicaments
UK MHRA: Drug Safety Update (July 2015)
L’ANSM confie à la CCI Paris Ile-de-France la gestion des certificats d’exportation de produits de santé
EMA: Pharmacovigilance Risk Assessment Committee confirms Chair and Vice-chair for new three year mandate
EMA: Draft zonisamide hard capsules 25, 50 and 100 mg, orodispersible tablets 25, 50, 100 and 300 mg product-specific bioequivalence guidance
EMA: Draft prasugrel film-coated tablets 5 and 10 mg product-specific bioequivalence guidance
EMA: Draft asenapine sublingual tablets 5 and 10 mg product-specific bioequivalence guidance
EMA: Public register of parallel distribution now available